A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis

BACKGROUND: Etanercept, a soluble tumor necrosis factor receptor, and acitretin have been shown to be effective in treating psoriasis. Acitretin is widely used in Korea. However, the combination of etanercept plus acitretin has not been evaluated among Korean patients with psoriasis. The objective o...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Joo-Heung, Youn, Jai-Il, Kim, Tae-Yoon, Choi, Jee-Ho, Park, Chul-Jong, Choe, Yong-Beom, Song, Hae-Jun, Kim, Nack-In, Kim, Kwang-Joong, Lee, Jeung-Hoon, Yoo, Hyun-Jeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960797/
https://www.ncbi.nlm.nih.gov/pubmed/27455955
http://dx.doi.org/10.1186/s12895-016-0048-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960797/
https://www.ncbi.nlm.nih.gov/pubmed/27455955
http://dx.doi.org/10.1186/s12895-016-0048-z

Ejemplares similares